A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950) - PubMed
5 hours ago
- #head and neck cancer
- #ATR inhibitor
- #chemoradiation
- Phase 1 study of berzosertib (M6620, VX-970) combined with cisplatin and radiation in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
- ATR inhibition by berzosertib aims to sensitize tumor cells to radiation and chemotherapy.
- Patients received daily radiation (70 Gy) and weekly cisplatin (40 mg/m²) with escalating doses of berzosertib (120, 160, 200 mg/m²).
- Dose-limiting toxicities included thrombocytopenia, respiratory failure, renal injury, and inability to complete radiation.
- Recommended phase 2 dose of berzosertib was 200 mg/m² weekly.
- Objective response rates were 78.8% in evaluable patients and 63.6% in the expansion cohort.
- Berzosertib was safe but did not improve complete response rates in LA-HNSCC.